keyword
MENU ▼
Read by QxMD icon Read
search

primary peritoneal cancer

keyword
https://www.readbyqxmd.com/read/29142465/efficacy-of-vinorelbine-combined-with-low-dose-methotrexate-for-treatment-of-inoperable-desmoid-tumor-and-prognostic-factor-analysis
#1
Shu Li, Zhengfu Fan, Zhiwei Fang, Jiayong Liu, Chujie Bai, Ruifeng Xue, Lu Zhang, Tian Gao
Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor (DT) and analyze the prognostic factors. Methods: From November 2008 to April 2016, 71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors, Peking University Cancer Hospital & Institute, and enrolled in this retrospective study. The chemotherapy duration is one year. The efficacy of chemotherapy and the prognosis were observed...
October 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/29136604/extragenital-malignant-mixed-mesodermal-tumor-a-case-report
#2
Mauro Del Papa, Gabriele D'Amata, Fulvio Manzi, Luca Musmeci, Marco Crovaro, Carlo Buonocore, Gaetano Florio, Andrea Giannetti
INTRODUCTION: Primary malignant mixed mesodermal tumor (MMMt, also called malignant mixed Mullerian tumor and designated in the WHO classification of female genital tract neoplasms as carcinosarcoma) is an infrequent tumor that develops usually in the uterus and more rarely in the ovary. Extragenital tumor, including primary peritoneal MMMt, is an extremely rare and aggressive neoplasm with only few case reported in the literature. PRESENTATION OF CASE: We report a case of a 70-year's old female who presented with nausea and abdominal discomfort for 6 months...
November 9, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29135095/does-upfront-therapy-with-cytoreductive-surgery-and-hipec-confer-a-survival-benefit-in-patients-with-synchronous-gastric-peritoneal-carcinomatosis-when-compared-with-patients-with-metachronous-gastric-peritoneal-carcinomatosis
#3
Nikolaos Kopanakis, Elias Efstathiou, Dimitrios Sarris, John Spiliotis
Gastric cancer (GC) remains the second leading cause of cancer death worldwide, accounting for 8% of the total cases and 10% of total deaths in 2008. Surgery remains the curative treatment option for GC and the main reason for treatment failure is peritoneal recurrence which, according to the literature, occurs in 40-60% of the cases, despite extensive surgery including D2 lymph node dissection. The hyperthermic intraperitoneal chemotherapy (HIPEC) technique is increasingly used in the treatment of primary and digestive peritoneal carcinomatosis (PC), in association with cytoreductive surgery (CRS)...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29132061/synchronous-peritoneal-metastases-of-small-bowel-adenocarcinoma-insights-into-an-underexposed-clinical-phenomenon
#4
Laura M Legué, Geert A Simkens, Geert-Jan M Creemers, Valery E P P Lemmens, Ignace H J T de Hingh
BACKGROUND: The aim of this population-based study was to provide insight into the incidence, risk factors and treatment-related survival of patients with peritoneal metastases (PM) of small bowel adenocarcinoma (SBA). METHODS: Data from the Netherlands Cancer Registry were used. All patients diagnosed with SBA between 2005 and 2014 were included. The influence of patient and tumour characteristics on the odds of developing PM was analysed. Subsequently, for all further analyses, patients without synchronous PM of SBA were excluded...
November 10, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29130218/-clinical-significance-and-practice-points-of-conversion-therapy-for-gastric-cancer-with-peritoneal-metastasis
#5
Zhenggang Zhu
Gastric cancer with peritoneal dissemination is usually considered to be oncologically unresectable and is known to have a very poor prognosis. Despite recent advances in systemic chemotherapy, peritoneal dissemination due to advanced gastric cancer (AGC) still remains the most life-threatening type of metastasis and recurrence, which usually causes ascites accumulation, intestinal obstruction, or hydronephrosis, and then seriously impairs the quality of life. In general, the median survival time of these cases is reported to be just only 6-9 months...
October 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29128439/robotic-splenectomy-for-isolated-splenic-recurrence-of-endometrial-adenocarcinoma
#6
Valerio Gallotta, Marco D'Indinosante, Camilla Nero, Maria Teresa Giudice, Carmine Conte, Claudio Lodoli, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
OBJECTIVES: We present a rare case of an isolated intraparenchymal splenic metastasis of endometrial cancer managed with robotic-assisted surgery. METHODS: A 55-year-old patient with a history of endometrial cancer was found to have a splenic lesion during her follow-up exams. She underwent surgical staging (total hysterectomy, bilateral salpingo-oopherectomy, pelvic lymphadenectomy and peritoneal washing) in 2014 and the final pathologic findings showed an endometrioid endometrial adenocarcinoma, FIGO Stage IB G2...
November 8, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/29119533/18-fluorodeoxyglucose-positron-emission-tomography-predicts-recurrence-in-resected-pancreatic-ductal-adenocarcinoma
#7
Kyohei Ariake, Fuyuhiko Motoi, Hideo Shimomura, Masamichi Mizuma, Shimpei Maeda, Chiaki Terao, Yasuko Tatewaki, Hideo Ohtsuka, Koji Fukase, Kunihiro Masuda, Hiroki Hayashi, Tatsuyuki Takadate, Takeshi Naitoh, Yasuyuki Taki, Michiaki Unno
BACKGROUND: We aimed to determine whether treatment should be stratified according to 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) maximum standardized uptake values (SUVmax) in pancreatic ductal adenocarcinoma. METHODS: Patients who underwent preoperative 18F-FDG PET/CT between 2006 and 2014 (n = 138) were stratified into high (≥ 4.85) and low (< 4.85) PET groups. The clinicopathological characteristics and prognostic outcomes were analyzed retrospectively...
November 8, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29113652/examination-of-cancer-cells-exposed-to-gastric-serosa-by-serosal-stamp-cytology-plus-rt-pcr-is-useful-for-the-identification-of-gastric-cancer-patients-at-high-risk-of-peritoneal-recurrence
#8
Yuichiro Miki, Masakazu Yashiro, Kanae Ando, Tomohisa Okuno, Kishu Kitayama, Go Masuda, Tatsuro Tamura, Katsunobu Sakurai, Takahiro Toyokawa, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Masahiko Osawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: We sought to clarify the clinical value of the examination of cancer cells exposed to gastric serosa by our novel method of serosal stamp cytology and a real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis. METHOD: A total of 70 patients who underwent gastrectomy were enrolled. Stamp cytology specimens were obtained by stamping the gastric serosa at the primary gastric tumor lesion, followed by Papanicolaou's staining...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29111390/treatment-of-peritoneal-carcinomatosis-with-photodynamic-therapy-systematic-review-of-current-evidence
#9
REVIEW
Muhammad Qutayba Almerie, Gemma Gossedge, Kathleen E Wright, David G Jayne
BACKGROUND: Peritoneal carcinomatosis results when tumour cells implant and grow within the peritoneal cavity. Treatment and prognosis vary based on the primary cancer. Although therapy with intention-to-cure is offered to selective patients using cytoreductive surgery with chemotherapy, the prognosis remains poor for most of the patients. Photodynamic therapy (PDT) is a cancer-therapeutic modality where a photosensitiser is administered to patients and exerts a cytotoxic effect on cancer cells when excited by light of a specific wavelength...
October 27, 2017: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/29100454/peritoneal-recurrence-in-gastric-cancer-following-curative-resection-can-be-predicted-by-postoperative-but-not-preoperative-biomarkers-a-single-institution-study-of-320-cases
#10
Fan Wu, Chunmei Shi, Riping Wu, Zhiqing Huang, Qiang Chen
To determine the risk factors for peritoneal recurrence in gastric cancer patients after curative resection, we included 320 patients with stage I-III primary gastric cancer between January 2008 and June 2012. Data on each patient's surgical and pathological information, preoperative and postoperative tumor markers were collected and analyzed retrospectively. The risk factors for peritoneal recurrence were investigated by univariate and multivariate analysis. In patients with peritoneal recurrence, advanced T or N stage, low differentiation, vascular/lymphatic invasion, perineural invasion, and elevated postoperative CEA/CA19-9 were more common than in patients without peritoneal recurrence...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29094253/peritoneal-cancer-arising-after-total-abdominal-hysterectomy-and-bilateral-salpingo-oophorectomy-for-cervical-cancer-in-a-patient-with-right-breast-cancer-and-germline-mutation-of-brca1-gene-a-case-report-and-literature-review
#11
Michiko Harao, Jiro Ando, Hiroyuki Kamata, Nobuo Hoshi, Seiji Igarashi, Ryuzo Sekiguchi, Kokichi Sugano
Primary peritoneal carcinoma is usually advanced at diagnosis and curability is low unless the patient has a small tumor burden. Peritoneal carcinoma can occur in association with hereditary breast and ovarian cancer syndrome, which is thought to account for 5-6% of all breast cancer. Mutations of two breast cancer susceptibility genes, BRCA1 and BRCA2, are responsible for hereditary breast and ovarian cancer. Women with BRCA1/2 mutations often undergo risk-reducing salpingo-oophorectomy (RRSO) to prevent both ovarian and breast cancer...
November 1, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29080971/combination-chemotherapy-with-irinotecan-and-gemcitabine-for-taxane-platinum-resistant-refractory-ovarian-and-primary-peritoneal-cancer-a-multicenter-phase-i-ii-trial-gogo-ov-6
#12
Kiyoshi Yoshino, Shoji Kamiura, Takeshi Yokoi, Ruriko Nakae, Masami Fujita, Masahiko Takemura, Kazushige Adachi, Akinori Wakimoto, Takamichi Nishizaki, Yasuhiko Shiki, Tateki Tsutsui, Yuki Kanda, Eiji Kobayashi, Kae Hashimoto, Seiji Mabuchi, Yutaka Ueda, Kenjiro Sawada, Takuji Tomimatsu, Tadashi Kimura
PURPOSE: To develop a new therapeutic strategy for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancers, we evaluated the feasibility and efficacy of irinotecan and gemcitabine combination chemotherapy. METHODS: Patients with taxane/platinum-resistant/refractory cancer received escalating doses of irinotecan and gemcitabine (level 1: 80 and 800 mg/m(2), respectively; level 2: 100 and 1000 mg/m(2)) on days 1 and 8 on a 21-day cycle. Genotyping for UGT1A1*6 and *28 polymorphisms was performed for possible adverse irinotecan sensitivity...
October 28, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29079411/capecitabine-versus-s-1-as-adjuvant-chemotherapy-for-patients-with-stage-iii-colorectal-cancer-jcog0910-an-open-label-non-inferiority-randomised-phase-3-multicentre-trial
#13
Tetsuya Hamaguchi, Yasuhiro Shimada, Junki Mizusawa, Yusuke Kinugasa, Yukihide Kanemitsu, Masayuki Ohue, Shoichi Fujii, Nobuhiro Takiguchi, Toshimasa Yatsuoka, Yasumasa Takii, Hitoshi Ojima, Hiroyuki Masuko, Yoshiro Kubo, Hideyuki Mishima, Takashi Yamaguchi, Hiroyuki Bando, Toshihiko Sato, Takeshi Kato, Kenichi Nakamura, Haruhiko Fukuda, Yoshihiro Moriya
BACKGROUND: Adjuvant chemotherapy with oral fluoropyrimidine alone after D3/D2 lymph node dissection improves disease-free survival and overall survival in patients with stage III colon cancer. Adjuvant S-1 has been shown to be non-inferior to uracil and tegafur plus leucovorin in terms of disease-free survival. This study aims to confirm the non-inferiority of S-1 compared with capecitabine as adjuvant treatment in patients with stage III colorectal cancer. METHODS: This study was an open-label, non-inferiority, randomised, phase 3, multicentre trial done in 56 Japanese centres to assess the non-inferiority of S-1 to capecitabine as adjuvant chemotherapy...
October 24, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29076043/locally-advanced-colorectal-cancer-true-peritoneal-tumor-penetration-is-associated-with-peritoneal-metastases
#14
Charlotte E L Klaver, Nadine C M van Huijgevoort, Anthony de Buck van Overstraeten, Albert M Wolthuis, Pieter J Tanis, Jarmila D W van der Bilt, Xavier Sagaert, André D'Hoore
BACKGROUND: Findings show T4 colorectal cancer (CRC) to be a risk factor for the development of peritoneal metastases (PM). Heterogeneity regarding peritoneal involvement of T4 tumors might explain the wide range of reported PM incidences (8-50%). Hyperplastic and mesothelial inflammatory reactions complicate evaluation of the exact primary tumor involvement of the peritoneal layer. This retrospective cohort study aimed to assess the association between either inflammatory peritoneal reaction or peritoneal involvement of the primary tumor and the risk of PM...
October 26, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29066706/-three-cases-of-high-grade-malignant-cancer-of-unknown-primary-with-a-long-term-survival
#15
Kenji Gonda, Masahiko Shibata, Masami Yasuda, Yosuke Tachiya, Yuichi Hatakeyama, Koji Kono, Yuichi Rokkaku
We report 3unusual cases of cancer of unknown primary(CUP)with a long-term survival after chemotherapy. A 56-yearold man was diagnosed as having CUP with invasion of an enlarged carcinoma 20 cm in size to the pancreas and peritoneal dissemination. He received chemotherapy with paclitaxel, carboplatin, and gemcitabine. After the chemotherapy, CT scan and PET-CT revealed no evidence of disease, so tumor resection was performed. The subsequent pathological findings revealed no cancer and a complete pathological response...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29055648/prognostic-factors-in-patients-undergoing-primary-cytoreductive-surgery-for-figo-stage-iiic-ovarian-tubal-or-peritoneal-cancer
#16
Alpaslan Kaban, Samet Topuz, Pınar Saip, Hamdullah Sözen, Yavuz Salihoğlu
OBJECTIVE: The aim of the study is to investigate factors related to overall survival in advanced stage ovarian, tubal, or peritoneal cancer and to identify strong and weak prognostic factors. METHODS: We retrospectively reviewed 190 patients who underwent primary cytoreductive surgery between 2003 and 2013. RESULTS: Median overall survival duration was founded 58 months (95% CI 49-67). Five-year overall survival ratio was 48.5%. Presence of tumour at upper abdomen, suboptimal cytoreduction (residual >1 cm), surgery without lymphadenectomy, and presence of peritoneal ascites more than 1 L had a significantly negative effect on overall survival, but not histological grade and CA-125 level, by univariate Cox analysis...
October 18, 2017: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/29046790/intraluminal-rectal-cancer-metastasis-to-the-small-bowel-an-extremely-rare-case-report
#17
Paraskevas Stamopoulos, Nikolaos Machairas, Stylianos Kykalos, Afrodite Nonni, Gregory Kouraklis, Georgios C Sotiropoulos
Prolonged survival in patients suffering from colorectal cancer (CRC) may lead to the emergence of rare metastatic sites that are not well-documented in the literature. We herein describe a very rare case of an intraluminal small intestinal metastasis in a patient with previously resected CRC. A 71-year-old Caucasian male patient with a history of rectosigmoid junction cancer was initially treated with anterior resection. The tumor was classified as pT3pN0 (0/26) M0, stage II. Eighteen months after the primary surgery, local recurrence was detected in the presacral region, and the patient received combined image-guided radiotherapy and chemotherapy...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29043410/determination-of-the-absolute-oral-bioavailability-of-niraparib-by-simultaneous-administration-of-a-14-c-microtracer-and-therapeutic-dose-in-cancer-patients
#18
L van Andel, H Rosing, Z Zhang, L Hughes, V Kansra, M Sanghvi, M M Tibben, A Gebretensae, J H M Schellens, J H Beijnen
INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The pivotal phase III clinical trial has shown improved progression-free survival in patients receiving niraparib compared with those receiving placebo...
October 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29033584/dna-ploidy-and-s-phase-fraction-analysis-in-peritoneal-carcinomatosis-from-ovarian-cancer-correlation-with-clinical-pathological-factors-and-response-to-chemotherapy
#19
Silvia Carloni, Giulia Gallerani, Anna Tesei, Emanuela Scarpi, Giorgio Maria Verdecchia, Salvatore Virzì, Francesco Fabbri, Chiara Arienti
OBJECTIVE: We investigated the correlation between ploidy or S-phase fraction (SPF) and the clinical pathological characteristics of patients with peritoneal carcinomatosis from ovarian cancer. We also assessed their relation with the in vivo and in vitro response to several chemotherapeutic agents. PATIENTS AND METHODS: Fifty-three patients with peritoneal carcinomatosis from ovarian cancer were enrolled. Frozen tumor tissue was dissociated by a detergent-trypsin method, and the resulting cell suspension was stained with RNase A and propidium iodide...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29029123/outcome-of-elevated-ca125-values-from-primary-care-following-implementation-of-ovarian-cancer-guidelines
#20
S Michael Crawford, Colin Evans
Background: Ovarian cancer presents later in the UK compared to economically similar countries. National guidance suggests measuring CA125 in primary care as a means of bringing patients to specialist attention. Aim: To investigate the outcome of CA125 values measured in accordance with this policy. Setting and design: Examination of the laboratory records of female patients from the usual catchment population of one general hospital in whom CA125 was measured from primary care in a calendar year...
September 28, 2017: Family Practice
keyword
keyword
63801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"